A Phase III Randomised comparison of Gemcitabine/Carboplatin with Cisplatin/Etoposide in Small Cell Lung Cancer

ISRCTN ISRCTN39679215
DOI https://doi.org/10.1186/ISRCTN39679215
Secondary identifying numbers Study 10
Submission date
19/08/2002
Registration date
19/08/2002
Last edited
29/10/2021
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr - -
Scientific

UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
NW1 2DA
United Kingdom

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeNot Specified
Scientific titleA Phase III Randomised comparison of Gemcitabine/Carboplatin with Cisplatin/Etoposide in Small Cell Lung Cancer
Study objectivesNot provided at time of registration
Ethics approval(s)Not provided at time of registration
Health condition(s) or problem(s) studiedLung (small cell) cancer
Intervention1. GC Arm: 3-weekly regimen (6 cycles) Gemcitabine 1200 mg/m(2) IV (Day 1 and 8) Carboplatin (AUC 5) Dose in mg calculated according to the formula: Dose = Target area under curve x (creatinine clearance + 25) IV (Day1)

2. PE Arm: 3-weekly regime (6 cycles): Cisplatin 60 mg/m2 IV Day 1 Etoposide 120 mg/m2 IV (Day 1) and 100 mg bd po (days 2 and 3)
Intervention typeDrug
Pharmaceutical study type(s)
PhasePhase III
Drug / device / biological / vaccine name(s)Cancer drugs
Primary outcome measureNot provided at time of registration
Secondary outcome measuresNot provided at time of registration
Overall study start date01/01/1996
Completion date31/10/2001

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participantsNot provided at time of registration
Total final enrolment241
Key inclusion criteria1. Histologically or cytologically proven small cell anaplastic carcinoma of the lung
2. Extensive stage disease or limited stage but locally advanced or limited stage with poor prognostic factors
3. Measurable or evaluable disease
4. Adequate renal function for chemotherapy
5. Age 18 years or above
6. Adequate contraception for women of child bearing potential
7. Written informed consent
Key exclusion criteriaNot provided at time of registration
Date of first enrolment01/01/1996
Date of final enrolment31/10/2001

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

UKCCCR Register Co-ordinator
London
NW1 2DA
United Kingdom

Sponsor information

NCRI CSG and London Lung Cancer Group (UK)
Research organisation

-
London
-
United Kingdom

ROR logo "ROR" https://ror.org/02mp0vf47

Funders

Funder type

Research organisation

NCRI CSG and London Lung Cancer Group (UK)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing planNot provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/06/2001 Yes No
Plain English results 08/09/2009 29/10/2021 No Yes

Editorial Notes

29/10/2021: The following changes have been made:
1. The Cancer Research UK lay results summary has been added.
2. The total final enrolment number has been added.